Loading patent…
AssigneeThe Regents of the University of Colorado, a body corporate
InventorsGlen Joel Weiss, Lynne Bemis, Paul A. Bunn, JR., Wilber A/ Franklin
Estimating the term…
Provided herein are methods for identifying a cancer patient responsive to treatment with an EGFR tyrosine kinase inhibitor. One method comprises obtaining a biopsy from the patient and measuring the number of copies of miR-128b in DNA extracted from the biopsy. A patient responsive to EGFR tyrosine kinase inhibitor treatment has a cancer with less than two copies of miR-128b DNA. Another method comprises measuring miR-128b or miR-128a level in a biopsy obtained from the patient and comparing that level to miR-128b or miR-128a level in a normal tissue sample. A patient responsive to treatment with an EGFR tyrosine kinase inhibitor has a cancer expressing a lower level of miR-128b or miR-128a relative to normal tissue. Further provided herein are methods for treating cancer in a patient in need thereof. One method comprises measuring the level of miR-128b or miR-128a in a biopsy obtained from the patient and administering to the patient an EGFR tyrosine kinase inhibitor. Another method comprises measuring the number of copies of miR-128b in DNA extracted from a biopsy obtained from the patient and administering to the patient an EGFR tyrosine kinase inhibitor. A further method comprises administering to a cancer patient an EGFR tyrosine kinase inhibitor and an miR-128b inhibitor, administering an miR-128a mimic, or administering an miR-128b mimic. Also provided herein are compositions used to treat cancer in a patient. The compositions comprise an EGFR tyrosine kinase inhibitor and an miR-128b inhibitor (or an miR-128a inhibitor), and the cancer is characterized as having 2 or more copies of miR-128b DNA at the cellular level.
A method for identifying a cancer patient responsive to treatment with an EGFR tyrosine kinase inhibitor, the method comprising detecting a genomic loss of miR-128b in a cancer biopsy obtained from said cancer patient, wherein said genomic loss of miR-128b indicates said cancer patient is responsive to treatment with an EGFR tyrosine kinase inhibitor.
A method for identifying a cancer patient responsive to treatment with an EGFR tyrosine kinase inhibitor, the method comprising measuring miR-128b or miR-128a level in a biopsy obtained from the patient and comparing that level to an unaffected gene in the same tissue sample, wherein a patient responsive to treatment with an EGFR tyrosine kinase inhibitor has a cancer expressing a lower level of miR-128b or miR-128a relative to the unaffected gene.
A method for treating cancer in a patient in need thereof, the method comprising:
A method for treating cancer in a patient in need thereof, the method comprising:
A method for treating cancer, the method comprising administering to a cancer patient an EGFR tyrosine kinase inhibitor and a miR-128b inhibitor.
A method for treating cancer, the method comprising administering to a cancer patient a composition comprising a miR-128b
A method for treating cancer, the method comprising administering to a cancer patient a composition comprising a miR-128a mimic.
A method for treating cancer, the method comprising administering to a cancer patient a composition comprising a miR-128a inhibitor and an EGFR tyrosine kinase inhibitor.
A composition used to treat cancer in a patient, the composition comprising an EGFR tyrosine kinase inhibitor and a miR-128b inhibitor, wherein the cancer is characterized as having a ratio of 0.5 or greater of miR-128b DNA to an unaffected gene at the cellular level.
A method for identifying a cancer therapeutic, the method comprising screening for compounds that target a miR-128b binding site or miR-128a binding site on a 3′ untranslated region of EGFR mRNA.
A method for identifying a cancer therapeutic, the method comprising screening for compounds that inhibit miR-128b, wherein the therapeutic is used in combination with an EGFR tyrosine kinase inhibitor to treat a cancer that overexpresses miR-128b.
A method for identifying a patient or patient population predisposed to cancer, the method comprising measuring the level of miR-128b, number of miR-128b DNA copies, or both in a biopsy obtained from the patient.
Dependencies are inferred from the claim text.